Epidermal growth factor

From WikiMD's WELLNESSPEDIA

(Redirected from Urogastrone)

MAPKpathway_diagram.svg

Epidermal growth factor (EGF) is a protein that stimulates cell growth, cell proliferation, and cell differentiation by binding to its receptor, EGFR (Epidermal Growth Factor Receptor). EGF is a member of the growth factor family and plays a crucial role in the regulation of cell growth, proliferation, and differentiation.

Discovery[edit]

EGF was first discovered by Stanley Cohen in 1962. Cohen's work on EGF earned him the Nobel Prize in Physiology or Medicine in 1986, which he shared with Rita Levi-Montalcini for their discoveries of growth factors.

Structure[edit]

EGF is a small polypeptide consisting of 53 amino acids and has a molecular weight of approximately 6.2 kDa. The structure of EGF includes three disulfide bonds that are essential for its biological activity.

Function[edit]

EGF functions by binding to the epidermal growth factor receptor on the cell surface. This binding triggers a cascade of downstream signaling pathways, including the MAPK/ERK pathway, the PI3K/AKT pathway, and the JAK/STAT pathway. These pathways lead to various cellular responses such as DNA synthesis, cell proliferation, and differentiation.

Role in Medicine[edit]

EGF has significant implications in medicine, particularly in the fields of oncology and wound healing. Overexpression of EGF and EGFR has been linked to various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Targeting the EGF/EGFR pathway is a therapeutic strategy in cancer treatment, with drugs such as gefitinib and erlotinib being used as EGFR inhibitors.

In wound healing, EGF promotes the regeneration of the epidermis and accelerates the healing process. EGF-containing topical treatments are used to enhance the healing of burns, ulcers, and other skin injuries.

Clinical Applications[edit]

EGF has been used in various clinical applications, including:

See also[edit]

References[edit]


External links[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.